[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100242450":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":24,"responsibleParty":38,"collaborators":41,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Hepatorenal syndrome group",null,"Patients with advanced cirrhosis who develope hepatorenal syndrome",{"label":13,"type":10,"description":14,"interventionNames":10},"Non-hepatorenal syndrome group","Patients with advanced cirrhosis who do not hepatorenal syndrome",[16],{"name":17,"affiliation":5,"role":18},"Desmond Yap, MD","PRINCIPAL_INVESTIGATOR",[20],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","85222553879","desmondy@hku.hk",[25],{"facility":26,"status":27,"city":28,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Queen Mary Hospital, Hong Kong","RECRUITING","Hong Kong","HK",{"type":31,"coordinates":32},"Point",[33,34],114.17469,22.27832,{"lat":34,"lon":33},[37],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},{"type":18,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Dr. Desmond Yat-Hin Yap","Clinical Assistant Professor",[42],{"name":43,"class":6},"The Hong Kong Society of Nephrology","100242450","use-of-novel-plasma-and-urinary-biomarkers-to-predict-the-development-of-hepatorenal-syndrome-in-cirrhotic-patients-100242450",false,"NCT02434445","Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients","Inclusion Criteria:\n\n* Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation\n* Willing to give informed consent\n\nExclusion Criteria:\n\n* Patients with co-existing renal diseases","ALL","18 Years","90 Years",{"count":54,"type":55},100,"ESTIMATED","OBSERVATIONAL","This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.",[59],"Hepatorenal Syndrome","2024-12-13",{"date":62,"type":63},"2024-12-16","ACTUAL",{"date":65,"type":63},"2012-06-01",{"date":67,"type":55},"2028-12-31",{"name":5,"class":6},1]